23.10p+0.80 (+3.59%)26 Feb 2024, 07:54
Find out how to deal online from £1.50 in a SIPP, ISA or Dealing account.
Jump to:

Oncimmune Holdings PLC Fundamentals

Company NameOncimmune Holdings PLCLast Updated2024-02-26
IndustryBiotechnologySectorHealthcare
Shares in Issue74.142 mMarket Cap£17.13 m
PE Ratio0.00Dividend per Share0
Dividend Yield0Dividend Cover0
EPS-£0.16EPS Growth (%)0
PEG0DPS Growth (%)0
Debt Ratio1.3233Debt Equity Ratio0
Asset Equity Ratio-1.3003Cash Equity Ratio-0.1288
Quick Ratio0.3169Current Ratio0.37
Price To Book Value0ROCE0

Oncimmune Holdings PLC Dividends

TypeEx-DatePay DateCurrencyNet DividendYear Total

Oncimmune Holdings PLC Company Financials

Assets20222021
Tangible Assets£1.34 m£1.59 m
Intangible Assets£4.59 m£5.69 m
Investments00
Total Fixed Assets£6.55 m£8.22 m
Stocks£430,000.00£143,000.00
Debtors£1.36 m£1.64 m
Cash & Equivalents£1.43 m£8.63 m
Other Assets00
Total Assets£10.16 m£19.36 m
Liabilities20222021
Creditors within 1 year£7.82 m£4.85 m
Creditors after 1 year£6.52 m£9.28 m
Other Liabilities00
Total Liabilities£14.34 m£14.13 m
Net assets-£4.18 m£5.23 m
Equity20222021
Called up share capital£695,000.00£691,000.00
Share Premium£40.63 m£40.50 m
Profit / Loss-£11.56 m-£6.06 m
Other Equity-£4.18 m£5.23 m
Preference & Minorities00
Total Capital Employed-£4.18 m£5.23 m
Ratios20222021
Debt Ratio£0.570
Debt-to-Equity£1.320
Assets / Equity-1.3003-1.3003
Cash / Equity-0.1288-0.1288
EPS-£0.17-£0.08
Cash Flow20222021
Cash from operating activities-£6.87 m-£4.53 m
Cashflow before financing-£6.22 m£5.25 m
Increase in Cash-£7.15 m£4.40 m
Income20222021
Turnover£3.79 m£3.72 m
Cost of sales£1.96 m£865,000.00
Gross Profit£1.83 m£2.86 m
Operating Profit-£10.01 m-£5.14 m
Pre-Tax profit-£11.56 m-£6.06 m

Oncimmune Holdings PLC Company Background

SectorHealthcare
ActivitiesOncimmune Holdings PLC is engaged in diagnosing cancer. It is involved in the development, manufacture, and commercialization of personalized immunodiagnostics for the screening, detection and care of cancer. The company's operating segment includes Early CDT Lung and ImmunoINSIGHTS.
Latest Interim Date31 May 2023
Latest Fiscal Year End Date27 Feb 2023

Oncimmune Holdings PLC Directors

AppointedNamePosition
2016-11-07Mr. Andrew Vaughan UnittNon-Executive Director
2020-05-04Mr. Richard Simon SharpNon-Executive Director
2023-02-27Mr. Alistair MacdonaldNon-Executive Director,Chairman
2022-07-08Mr. Meinhard Folkert SchmidtNon-Executive Director,Chairman
2020-06-04Mr. Geoffrey Neil Hamilton-FairleyNon-Executive Director,Vice Chairman
2016-06-06Mr. Robert Hoyles PageExecutive Director,Chief Financial Officer
2023-10-12Mr. Timothy Brian BuntingNon-Executive Director,Deputy Chairman
2019-11-05Mr. Andrew MilletExecutive Director,Chief Financial Officer and Company Secretary
2020-06-04Mr. Carsten SchroederNon-Executive Director
2023-07-12Dr. Adam Mark Hill MB PhDExecutive Director,Chief Executive Officer
2021-01-19Dr. To CheungNon-Executive Director
2022-11-04Mr. Matthew HallExecutive Director,Chief Financial Officer
2023-01-13Mr. John Howard GooldNon-Executive Director
2023-12-11Mr. Martin John GouldstoneExecutive Director,Chief Executive Officer

Oncimmune Holdings PLC Contact Details

Company NameOncimmune Holdings PLC
AddressHucknall Road, Clinical Sciences Building, City Hospital, Nottingham, NG5 1PB
Telephone
Websitehttps://www.oncimmune.com

Oncimmune Holdings PLC Advisors

Nominated AdviserZeus Capital Ltd
Phone+44 2038295000
AuditorGrant Thornton (UK) LLP
Phone+44 1908660666
Fax+44 1908690180
StockbrokerZeus Capital Ltd
Phone+44 2038295000
RegistrarCapita Asset Services
Phone+44 8716640300
Fax+44 2086392342
Financial PR AdviserConsilium Strategic Communications
Phone+44 2037095700
SolicitorPeachey & Co LLP
Phone(020) 7316 5200
Fax(020) 7316 5222